Related Projects
The AutoCRAT team have close connections with other projects and initiatives working in regenerative medicine and life sciences engineering. Some of these initiatives are set out below.
AUTOSTEM: The full title of the AUTOSTEM Project was “Development of closed, scalable and automated robotic systems for therapeutic stem cell manufacturing: aseptic systems from Donor-to-Patient”. AUTOSTEM was a H2020 EU funded project which ran from 1 January 2016 to 31 December 2018. AUTOSTEM and AutoCRAT have some common partners and AUTOSTEM will form an important building block for the AutoCRAT Regenerative Medicine Factory (ARM-F). Prof. Mary Murphy of NUIG (Coordinator of AutoCRAT) was also the Coordinator of AUTOSTEM.
In the AIDPATH project, the partners from industry and research will build an automated and intelligent facility over a period of four years that is capable of producing targeted and patient-specific cell therapy directly at the point of treatment. In addition, the project addresses the integration of the facility into the hospital environment, taking into account logistics processes as well as data management and data security. AIDPATH is funded for four years under the funding code 101016909 from the European Commission’s Horizon 2020 funding measure.
The ten academic and industrial partners collaborating in the EU research project SBR (Smart Bone Regeneration) aim to improve treatment options for patients with large bone defects. By combining a smart implant with innovative tissue-engineering methods, we will work on a minimally invasive technique designed to complement existing clinical practices. Grant agreement No 874896.
JOINTPROMISE paves the way for high-volume, affordable production of entire biological joints, addressing a major socio-economic challenge of the European ageing society. JOINTPROMISE is a Research and Innovation Action funded by the European Commission under the Horizon 2020 framework program, call SC1-BHC-07-2019 – Regenerative medicine: from new insights to new applications (Grant agreement 874837).
Bone regeneration using engineered grafts must guide the growth of new bone and enable it to integrate into the surrounding tissue. To facilitate this process and improve bone regeneration, the EU-funded HEALIKICK project is working on a novel combinatorial approach that employs a granular graft material with a highly osteogenic coating seeded with pre-differentiated osteogenic adipose mesenchymal stromal cells (MSCs). Scientists will validate this approach initially in pre-clinical studies, with the aim to submit the required regulatory and technical developments for a clinical trial. They will also undertake the necessary optimisation and development activities to adapt this approach for the treatment of large bone defects.
STEMCELLFACTORY III: This project is funded through the European Regional Development Fund and is developing methods for the automated production of patient- and disease-specific induced pluripotent stem cells (iPS cells) from easy-to-obtain blood samples. The Project runs from 1 July 2017 to 30 June 2020 and is coordinated by AutoCRAT partner Fraunhofer IPT.
ADIPOA 2: This EU H2020 Project is carrying out a phase IIb study to assess the safety and efficacy of autologous (patient-derived) mesenchymal stromal cells in the treatment of advanced OA of the knee. The Project runs from 1 January 2015 to 31 December 2019. ADIPOA-2 and AutoCRAT have some common partners. NUIG is Coordinator.
PREMSTEM is a €9M research project funded by the European Union’s prestigious Horizon 2020 research and innovation programme, grant agreement No. 874721. This group of researchers from across the globe is developing a new regenerative stem cell therapy to repair the brain damage caused by premature birth, also known as encephalopathy of prematurity (EOP).
OActive’s mission is to improve healthcare by transforming and accelerating the OA diagnosis and prediction based on a more comprehensive and holistic understanding of disease pathophysiology, dynamics, and patient outcomes. Funded by the Horizon 2020 Programme under grant agreement No. 777159.